BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/22/2026 3:20:35 AM | Browse: 3 | Download: 4
Publication Name World Journal of Gastroenterology
Manuscript ID 119693
Country Spain
Received
2026-02-03 01:54
Peer-Review Started
2026-02-03 01:57
First Decision by Editorial Office Director
2026-02-14 07:54
Return for Revision
2026-02-14 07:54
Revised
2026-02-27 13:14
Publication Fee Transferred
Second Decision by Editor
2026-04-13 02:42
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director
2026-04-13 08:31
Articles in Press
2026-04-13 08:31
Edit the Manuscript by Language Editor
Typeset the Manuscript
2026-09-21 13:06
Publish the Manuscript Online
2026-09-22 03:20
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright ©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Observational Study
Article Title Real-world effectiveness and safety of risankizumab in multirefractory Crohn’s disease: A multicenter AIRIS-Crohn registry analysis
Manuscript Source Invited Manuscript
All Author List Antonio M Caballero-Mateos, Teresa Valdés-Delgado, Raúl Olmedo-Martín, Patricia Romero-Cara, María del Mar Martín-Rodríguez, Ana Lancho Muñoz, Melody Moreno-Barrueco, Raúl Gijón-Villanova, Nuria Fernández-Moreno, Francisco J Rodríguez-González, Álvaro Hernández-Martínez, Ana María Trapero-Martínez, Ana Bejarano-García, José Manuel Benitez Cantero, Francisco J Mata-Perdigón, Antonia Sáez-Díaz and Federico Argüelles-Arias
ORCID
Author(s) ORCID Number
Antonio M Caballero-Mateos http://orcid.org/0000-0002-3425-7758
Teresa Valdés-Delgado http://orcid.org/0000-0002-2142-5142
Raúl Olmedo-Martín http://orcid.org/0000-0002-7894-6213
María del Mar Martín-Rodríguez http://orcid.org/0000-0002-2140-7825
Francisco J Rodríguez-González http://orcid.org/0009-0000-5369-709X
Álvaro Hernández-Martínez http://orcid.org/0000-0002-1710-4506
Federico Argüelles-Arias http://orcid.org/0000-0003-3646-8919
Funding Agency and Grant Number
Corresponding Author Teresa Valdés-Delgado, Department of Gastroenterology, Virgen Macarena University Hospital, Dr. Fedriani, Seville 41009, Spain. teresavaldes4@hotmail.com
Key Words Crohn’s disease; Inflammatory bowel disease; Risankizumab; Real-world evidence; Interleukin-12/23
Core Tip Risankizumab, a selective interleukin-23p19 inhibitor, emerges as a promising therapeutic option for patients with multirefractory Crohn’s disease. This multicenter real-world study of 205 patients demonstrates that risankizumab rapidly achieves clinical remission (49% at week 12) and maintains steroid-free remission in over 40% of patients throughout one-year follow-up. The excellent safety profile and high treatment persistence (> 90%) establish interleukin-23 blockade as a key strategy for patients with limited biologic alternatives in routine clinical practice.
Publish Date 2026-09-22 03:20
Citation

Caballero-Mateos AM, Valdés-Delgado T, Olmedo-Martín R, Romero-Cara P, Martín-Rodríguez MDM, Lancho Muñoz A, Moreno-Barrueco M, Gijón-Villanova R, Fernández-Moreno N, Rodríguez-González FJ, Hernández-Martínez Á, Trapero-Martínez AM, Bejarano-García A, Benitez Cantero JM, Mata-Perdigón FJ, Sáez-Díaz A, Argüelles-Arias F. Real-world effectiveness and safety of risankizumab in multirefractory Crohn’s disease: A multicenter AIRIS-Crohn registry analysis. World J Gastroenterol 2026; 32(42): 119693

URL https://www.wjgnet.com/1007-9327/full/v32/i42/119693.htm
DOI https://doi.org/10.3748/wjg.119693
Full Article (PDF) WJG-32-119693-with-cover.pdf
STROBE Statement 119693-STROBE-statement.pdf
Manuscript File 119693_Auto_Edited_031532.docx
Answering Reviewers 119693-answering-reviewers.pdf
Audio Core Tip 119693-audio.m4a
Biostatistics Review Certificate 119693-biostatistics-statement.pdf
Conflict-of-Interest Disclosure Form 119693-conflict-of-interest-statement.pdf
Copyright License Agreement 119693-copyright-assignment.pdf
Signed Informed Consent Form(s) or Document(s) 119693-informed-consent-statement.pdf
Institutional Review Board Approval Form or Document 119693-institutional-review-board-statement.pdf
Non-Native Speakers of English Editing Certificate 119693-non-native-speakers.pdf
Supplementary Material 119693-supplementary-material.pdf
Peer-review Report 119693-peer-reviews.pdf
Scientific Misconduct Check 119693-scientific-misconduct-check.png
CrossCheck Report 119693-crosscheck-report.pdf